AstraZeneca to buy China's Gracell Biotechnologies for $1.2 bn

Anglo-Swedish multinational pharmaceutical and biotechnology company AstraZeneca has agreed to acquire China-based Gracell Biotechnologies Inc, for about $1.2 billion.AstraZeneca has entered into a definitive agreement to acquire Gracell, a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases.